{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:57:51Z","timestamp":1793656671007,"version":"4.5.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","celltherapyjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.jcyt.2025.01.005","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T08:25:55Z","timestamp":1737188755000},"page":"413-416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["ISCT MSC committee statement on the US FDA approval of allogenic bone-marrow mesenchymal stromal cells"],"prefix":"10.1016","volume":"27","author":[{"given":"Katarina Le","family":"Blanc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Dazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"English","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Farge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Galipeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin M.","family":"Horwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadir","family":"Kadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Krampera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj Mathew","family":"Lalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Nolta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita M.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sowmya","family":"Viswanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9419","key":"10.1016\/j.jcyt.2025.01.005_bib0001","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/S0140-6736(04)16104-7","article-title":"Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells","volume":"363","author":"Le Blanc","year":"2004","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jcyt.2025.01.005_bib0002","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1097\/01.tp.0000214462.63943.14","article-title":"Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease","volume":"81","author":"Ringd\u00e9n","year":"2006","journal-title":"Transplantation"},{"issue":"9624","key":"10.1016\/j.jcyt.2025.01.005_bib0003","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","article-title":"Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study","volume":"371","author":"Le Blanc","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2025.01.005_bib0004","unstructured":"ClinicalTrials.gov. Mesenchymal stem cells OR mesenchymal stromal cells OR MSCs | Card Results | ClinicalTrials.gov [Internet]. [cited 2025 Jan 2]. Available from:https:\/\/clinicaltrials.gov\/search?intr=Mesenchymal20Stem20Cells20OR20mesenchymal20stromal20cells20OR20MSCs"},{"key":"10.1016\/j.jcyt.2025.01.005_bib0005","unstructured":"Myers C. Osiris Therapeutics Announces Preliminary Results for Prochymal Phase III GVHD Trials | Fierce Biotech [Internet]. 2009 [cited 2025 Jan 2]. Available from:https:\/\/www.fiercebiotech.com\/biotech\/osiris-therapeutics-announces-preliminary-results-for-prochymal-phase-iii-gvhd-trials"},{"issue":"3","key":"10.1016\/j.jcyt.2025.01.005_bib0006","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1164\/rccm.202201-0157OC","article-title":"A randomized trial of mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome from COVID-19","volume":"207","author":"Bowdish","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcyt.2025.01.005_bib0007","unstructured":"Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios [Internet]. [cited 2025 Jan 2]. Available from:https:\/\/www.athersys.com\/investors\/press-releases\/press-release-details\/2023\/Athersys-Reports-Interim-Analysis-Results-of-MASTERS-2-Clinical-Study-with-MultiStem-in-Ischemic-Stroke-Signs-Memorandum-of-Understanding-MOU-for-Global-ARDS-License-with-Healios\/default.aspx"},{"issue":"9","key":"10.1016\/j.jcyt.2025.01.005_bib0008","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jacc.2022.11.061","article-title":"Randomized trial of targeted transendocardial mesenchymal precursor cell therapy in patients with heart failure","volume":"81","author":"Perin","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jcyt.2025.01.005_bib0009","doi-asserted-by":"crossref","first-page":"S169","DOI":"10.1016\/j.bbmt.2009.12.057","article-title":"Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-controlled, multicenter phase III trial in GVHD","volume":"16","author":"Martin","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jcyt.2025.01.005_bib0010","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.bbmt.2020.01.026","article-title":"Study 275: Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-versus-Host Disease in Children","volume":"26","author":"Kurtzberg","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jcyt.2025.01.005_bib0011","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nbt1213-1061","article-title":"Mesoblast acquires Osiris\u2019 stem cell business","volume":"31","author":"Waltz","year":"2013","journal-title":"Nature Biotechnology"},{"issue":"5","key":"10.1016\/j.jcyt.2025.01.005_bib0012","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.bbmt.2020.01.018","article-title":"A phase 3, single-arm, prospective study of remestemcel-L, ex vivo culture-expanded adult human mesenchymal stromal cells for the treatment of pediatric patients who failed to respond to steroid treatment for acute graft-versus-host disease","volume":"26","author":"Kurtzberg","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jcyt.2025.01.005_bib0013","unstructured":"Limited M. GlobeNewswire News Room. 2020 [cited 2021 Feb 10]. Mesoblast receives complete response letter from the FDA for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children. Available from:http:\/\/www.globenewswire.com\/news-release\/2020\/10\/01\/2102679\/0\/en\/Mesoblast-Receives-Complete-Response-Letter-From-the-FDA-for-Biologics-License-Application-for-Steroid-Refractory-Acute-Graft-Versus-Host-Disease-in-Children.html"},{"key":"10.1016\/j.jcyt.2025.01.005_bib0014","unstructured":"Limited M. GlobeNewswire News Room. 2023 [cited 2025 Jan 2]. Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children. Available from:https:\/\/www.globenewswire.com\/news-release\/2023\/08\/04\/2718706\/0\/en\/Mesoblast-Receives-Complete-Response-From-U-S-Food-and-Drug-Administration-for-Biologics-License-Application-for-Steroid-Refractory-Acute-Graft-Versus-Host-Disease-in-Children.html"},{"key":"10.1016\/j.jcyt.2025.01.005_bib0015","unstructured":"Commissioner of the. FDA. FDA; 2024 [cited 2025 Jan 2]. FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-Refractory Acute Graft-versus-host Disease. Available from:https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-mesenchymal-stromal-cell-therapy-treat-steroid-refractory-acute-graft-versus-host"},{"key":"10.1016\/j.jcyt.2025.01.005_bib0016","unstructured":"Report on the Deliberation Results [Internet]. [cited 2025 Jan 2]. Available from: https:\/\/www.pmda.go.jp\/files\/000215658.pdf"},{"issue":"2","key":"10.1016\/j.jcyt.2025.01.005_bib0017","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s12185-015-1915-9","article-title":"Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II\/III study","volume":"103","author":"Muroi","year":"2016","journal-title":"Int J Hematol"},{"issue":"10","key":"10.1016\/j.jcyt.2025.01.005_bib0018","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/s41409-021-01304-y","article-title":"Off-the-shelf bone marrow-derived mesenchymal stem cell treatment for acute graft-versus-host disease: real-world evidence","volume":"56","author":"Murata","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jcyt.2025.01.005_bib0019","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10557-018-6804-z","article-title":"Improvement in left ventricular function with intracoronary mesenchymal stem cell therapy in a patient with anterior wall ST-segment elevation myocardial infarction","volume":"32","author":"Kim","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"10.1016\/j.jcyt.2025.01.005_bib0020","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4252\/wjsc.v16.i3.257","article-title":"Long-term outcome of stem cell transplantation with and without anti-tumor necrotic factor therapy in perianal fistula with Crohn's disease","volume":"16","author":"Park","year":"2024","journal-title":"World Journal of Stem Cells"},{"key":"10.1016\/j.jcyt.2025.01.005_bib0021","unstructured":"MEDIPOST [Internet]. 2023 [cited 2025 Jan 3]. CARTISTEM\u00ae Treatment of repetitive and\/or traumatic cartilage degeneration including degenerative osteoarthritis (OA) without age limit. Available from: https:\/\/en.medi-post.co.kr\/cartistem"},{"key":"10.1016\/j.jcyt.2025.01.005_bib0022","unstructured":"Corestemchemon, Inc. Evaluation the efficacy and safety of mutiple lenzumestrocel (Neuronata-R\u00ae Inj.) Treatment in Patients With ALS (ALSummit) [Internet]. clinicaltrials.gov; 2024 Oct [cited 2025 Jan 2]. Report No.: NCT04745299. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04745299"},{"issue":"3","key":"10.1016\/j.jcyt.2025.01.005_bib0023","doi-asserted-by":"crossref","first-page":"689","DOI":"10.5966\/sctm.2016-0237","article-title":"Administration of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells in critical limb ischemia due to Buerger's disease: Phase II study report suggests clinical efficacy","volume":"6","author":"Gupta","year":"2017","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.jcyt.2025.01.005_bib0024","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/1479-5876-11-143","article-title":"A double blind randomized placebo controlled phase I\/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia","volume":"11","author":"Gupta","year":"2013","journal-title":"J Transl Med"},{"issue":"9","key":"10.1016\/j.jcyt.2025.01.005_bib0025","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1177\/03635465231180323","article-title":"Efficacy and safety of stempeucel in osteoarthritis of the knee: a phase 3 randomized, double-blind, multicenter, placebo-controlled study","volume":"51","author":"Gupta","year":"2023","journal-title":"Am J Sports Med"},{"issue":"1","key":"10.1016\/j.jcyt.2025.01.005_bib0026","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s13075-016-1195-7","article-title":"Efficacy and safety of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells (Stempeucel\u00ae): preclinical and clinical trial in osteoarthritis of the knee joint","volume":"18","author":"Gupta","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jcyt.2025.01.005_bib0027","unstructured":"1st stem cell therapy, new HIV drug approved [Internet]. [cited 2025 Jan 7]. Available from: https:\/\/english.nmpa.gov.cn\/2025-01\/06\/c_1061969.htm"},{"issue":"10051","key":"10.1016\/j.jcyt.2025.01.005_bib0028","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S0140-6736(16)31203-X","article-title":"Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial","volume":"388","author":"Pan\u00e9s","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2025.01.005_bib0029","unstructured":"Alofisel withdrawn from the EU market | European Medicines Agency (EMA) [Internet]. 2024 [cited 2025 Jan 2]. Available from: https:\/\/www.ema.europa.eu\/en\/news\/alofisel-withdrawn-eu-market"},{"issue":"Supplement_1","key":"10.1016\/j.jcyt.2025.01.005_bib0030","doi-asserted-by":"crossref","first-page":"i34","DOI":"10.1093\/ecco-jcc\/jjad212.0018","article-title":"OP18 Efficacy and safety of darvadstrocel treatment in patients with complex perianal fistulas and Crohn's disease: results from the global ADMIRE-CD II phase 3 study","volume":"18","author":"Serclova","year":"2024","journal-title":"J Crohns Colitis"},{"issue":"3","key":"10.1016\/j.jcyt.2025.01.005_bib0031","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jcyt.2022.11.011","article-title":"Misconceptions, hurdles and recommendations regarding the use of mesenchymal stem\/stromal cells in perianal Crohn disease","volume":"25","author":"Ciccocioppo","year":"2023","journal-title":"Cytotherapy"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925000301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324925000301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T08:24:39Z","timestamp":1744446279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324925000301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1465324925000301"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.01.005","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ISCT MSC committee statement on the US FDA approval of allogenic bone-marrow mesenchymal stromal cells","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2025.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of International Society for Cell & Gene Therapy.","name":"copyright","label":"Copyright"}]}}